William Baek
Neurology · Upland, CANPI 1326095977
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,425 of the $62,151 with a category attached, or 68.3%. AbbVie accounts for 75.3% of it on its own, with 45 other manufacturers making up the rest. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 651 payments — averaging $95.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$47K
- Argenx US, Inc.$3K
- UCB, Inc.$2K
- Biogen$2K
- Lundbeck LLC$2K
- AstraZeneca$917
- plus $6K from 40 others
Across 1 payment — averaging $2028.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$4,5257%
- Speaking & faculty fees$42,42568%
- Travel & lodging$7911%
- Food & beverage$14,04523%
- Education$3641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$34,643
- QULIPTA$19,900
- VYVGART$2,300
- VYEPTI$1,275
- TYSABRI$600
- ULTOMIRIS$414
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$209
- Austedo XR$125
- Mavenclad$125
- Vumerity$125
How this compares
$62,151 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $541,661 |
| Austedo XrDeutetrabenazine | 19 | $238,755 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $208,687 |
| VumerityDiroximel Fumarate | 15 | $179,529 |
| NuplazidPimavanserin Tartrate | 13 | $82,959 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $79,037 |
| BanzelRufinamide | 13 | $77,426 |
| InbrijaLevodopa | 32 | $60,593 |
| VimpatLacosamide | 26 | $56,901 |
| GocovriAmantadine Hcl | 18 | $46,123 |
| NeuproRotigotine | 28 | $38,544 |
| UbrelvyUbrogepant | 31 | $32,489 |
| QuliptaAtogepant | 22 | $23,547 |
| Nurtec OdtRimegepant Sulfate | 11 | $15,561 |
| Selegiline Hcl | 87 | $11,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $57 | $541,66117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $425 | $238,75519 claims |
| BiogenVumerity | $1,923 | $179,52915 claims |
| UCB, Inc.Vimpat, Neupro | $1,986 | $95,44554 claims |
| PfizerOctagam, Nurtec Odt | $596 | $94,59723 claims |
| Acadia Pharmaceuticals IncNuplazid | $125 | $82,95913 claims |
| Eisai Inc.Banzel | $48 | $77,42613 claims |
| AbbVieUbrelvy, Qulipta | $46,809 | $56,03653 claims |
| MDD US Operations, LLCGocovri | $180 | $46,12318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Upland
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.